The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Open accessAbstract
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.ObjectivesThis double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.MethodsParticipants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.ResultsPsilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.ConclusionsUnder supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been repeatedly found that psychedelic-induced mystical-type experiences and ego dissolution, the latter a phenomenon characterized by the reduction in self-referential awareness, disruption self-world boundaries, and increased feelings of unity with one’s surroundings (55), correlates with long-term (positive) outcomes (23, 52–54, 56–58).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the active placebo group, both groups which received a high dose of psilocybin reported significantly higher enhancements in mood, well-being and life satisfaction, as assessed by the Persisting Effects Questionnaire (87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
The cited source says what the claim attributes to it.
In the citing paper
“5 mg of psilocybin was shown to induce subjective changes significantly greater than those of an inert placebo; [76]”
The cited source says what the claim attributes to it.
In the citing paper
“with high mystical experience scores associated with 30 mg/70 kg of psilocybin [76]”
The cited source says what the claim attributes to it.
In the citing paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Mindfulness meditation and mindfulness-based interventions can augment positive affect in healthy and clinical populations acutely and long-term (10, 88) and a similar mood-enhancing potential has been demonstrated for psychedelics such as psilocybin (29, 38, 60, 83, 87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Controlled studies where subjects achieved mystical experiences under the effects of psilocybin showed personal long-term benefits (Griffiths et al., 2008; Griffiths et al., 2011).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Griffiths et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“and a dose-response study in healthy volunteers suggested that optimum psilocybin dosing for eliciting a well-tolerated yet transcendent experience may be between 0·29 mg/kg and 0·43 mg/kg [32].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [32]
In the citing paper
“Self-reported increases in interpersonal closeness and positive/altruistic social effects were reported 1, 2, 6, and 14 months after one and two administrations of psilocybin (89–92).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 23×
“The questionnaire included three additional questions (see Griffiths et al. 2006 for more specific wording): (1) How personally meaningful was the experience?”
BackgroundMethodResultInfluentialSelf-citationThe Psychology of Religion: An Empirical Approach
Donahue, M. J., Hood, R. W., Spilka, B., Hunsberger, B. E., & Gorsuch, R. L. (1998) · Journal for the Scientific Study of Religion · doi:10.2307/1388044 · Cited by 1,339
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationMartin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
The Psychology of Religion: An Empirical Approach
Hall, C. M., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Journal for the Scientific Study of Religion · doi:10.2307/1386305 · Cited by 943
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Psychology of Religion: An Empirical Approach
Hunsberger, B. E., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Review of Religious Research · doi:10.2307/3511875 · Cited by 626
Research works printed but not linked: 5
- Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
- Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
- Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
- Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
- VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442–445
Cited by
Sorted by citations
Items 301–400 of 979
Lafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
The fibrinolytic system: A new target for treatment of depression with psychedelics
Idell, R. D., Florova, G., Komissarov, A. A., Shetty, S., Girard, R., & Idell, S. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.01.013 · Cited by 40
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 40
Do psychedelics change beliefs?
McGovern, H. T., Leptourgos, P., Hutchinson, B. T., & Corlett, P. R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06153-1 · Cited by 40
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
“Importantly, previous studies utilising psychedelicadministration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
BackgroundMethodResultInfluentialGarel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 39
Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism
Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433421 · Cited by 39
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0132 · Cited by 39
Müller, F., Holze, F., Dolder, P. C., Ley, L., Vizeli, P., Soltermann, A., Liechti, M. E., & Borgwardt, S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00906-2 · Cited by 39
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39
Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use
Sherwood, A. M., Claveau, R., Lancelotta, R., Kaylo, K. W., & Lenoch, K. (2020) · ACS Omega · doi:10.1021/acsomega.0c05099 · Cited by 38
Ching, T. H. W., Davis, A. K., Xin, Y., & Williams, M. T. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2025960 · Cited by 38
Castro Santos, H., & Gama Marques, J. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000128 · Cited by 37
Maij, D. L. R., & van Elk, M. (2018) · Consciousness and Cognition · doi:10.1016/j.concog.2018.09.010 · Cited by 37
Entity encounters and the therapeutic effect of the psychedelic mystical experience
Lutkajtis, A. (2021) · Journal of Evolutionary Psychology · doi:10.1556/2054.2020.00143 · Cited by 37
Liechti, M. E., & Holze, F. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_270 · Cited by 37
The Potential of Psychedelics for End of Life and Palliative Care
Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_278 · Cited by 37
Self-citationSøndergaard, A., Madsen, M. K., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.948729 · Cited by 37
Davis, A. K., Renn, E., Windham-Herman, A.-M., Polanco, M., & Barsuglia, J. P. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1487607 · Cited by 37
Fernández, X., dos Santos, R. G., Cutchet, M., Fondevila, S., González, D., Alcázar, M. Á., Riba, J., Bouso, J. C., & María Fábregas, J. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_11 · Cited by 36
Fauvel, B., Kangaslampi, S., Strika-Bruneau, L., Roméo, B., & Piolino, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2059796 · Cited by 36
Further psychometric exploration of the transliminality construct.
Evans, J. V., Lange, R., Houran, J., & Lynn, S. J. (2018) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000163 · Cited by 36
Psilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T. L., Hoskins, M. D., & Sessa, B. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2742 · Cited by 36
Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care
Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s096318012200007x · Cited by 36
Self-citationThe Altered States Database: Psychometric data from a systematic literature review
Prugger, J., Derdiyok, E., Dinkelacker, J., Costines, C., & Schmidt, T. T. (2022) · Scientific Data · doi:10.1038/s41597-022-01822-4 · Cited by 36
Argento, E., Socias, M. E., Hayashi, K., Choi, J., Mackay, L., Christie, D., Milloy, M., & DeBeck, K. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103518 · Cited by 35
Psilocybin-Assisted Compassion Focused Therapy for Depression
Pots, W. T. M., & Chakhssi, F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.812930 · Cited by 35
Kirlić, N., Lennard-Jones, M., Atli, M., Malievskaia, E., Modlin, N. L., Peck, S. K., Gaillard, A., Goodwin, G. M., & Koelpin, D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230884 · Cited by 35
Altered states of consciousness are related to higher sexual responsiveness
Costa, R. M., Pestana, J. O. M., Costa, D., & Wittmann, M. (2016) · Consciousness and Cognition · doi:10.1016/j.concog.2016.03.013 · Cited by 35
Lukić, V., Micić, R. J., ARSIC, B. B., Nedović, B., & Radosavljević, Ž. (2021) · Open Chemistry · doi:10.1515/chem-2021-0196 · Cited by 35
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
Daldegan‐Bueno, D., Maia, L. O., Massarentti, C. M., & Tófoli, L. F. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06063-2 · Cited by 34
Ertaş, A., Yiğitkan, S., & Orhan, İ. E. (2023) · Pharmaceuticals · doi:10.3390/ph16020171 · Cited by 34
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
BackgroundLancelotta, R. L., & Davis, A. K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1737763 · Cited by 33
Mindfulness, Mysticism, and Narrative Medicine
Lewis, B. E. (2016) · Journal of Medical Humanities · doi:10.1007/s10912-016-9387-3 · Cited by 33
Roscoe, J., & Lozy, O. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221085222 · Cited by 33
Ayahuasca and cancer treatment
Schenberg, E. E. (2013) · SAGE Open Medicine · doi:10.1177/2050312113508389 · Cited by 33
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
Puxty, D. J., Ramaekers, J. G., de la Torre, R., Farré, M., Pizarro, N., Pujadas, M., & Kuypers, K. P. C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00455 · Cited by 32
Psychedelics and hypnosis: Commonalities and therapeutic implications
Lemercier, C. E., & Terhune, D. B. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780714 · Cited by 32
Microdosing as a Response to the Meaning Crisis: A Qualitative Analysis
Petranker, R., Kim, J. J., & Anderson, T. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221075076 · Cited by 32
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 32
Psychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 32
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 32
Emmerich, N., & Humphries, B. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000099 · Cited by 32
Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland
Kangaslampi, S., Hausen, A., & Rauteenmaa, T. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1767321 · Cited by 31
Classification schemes of altered states of consciousness
Fort, L. D., Costines, C., Wittmann, M., Athena Demertzi, A., & Schmidt, T. T. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106178 · Cited by 31
Return of the psychedelics: Psilocybin for treatment resistant depression
Patra, S. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.010 · Cited by 31
Hupli, A., Berning, M., Zhuparris, A., & Fadiman, J. (2019) · Performance Enhancement & Health · doi:10.1016/j.peh.2019.01.001 · Cited by 31
Cannabis as entheogen: survey and interview data on the spiritual use of cannabis
Johnstad, P. G. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-020-00032-2 · Cited by 31
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 31
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Luppi, A. I., Girn, M., Rosas, F. E., Timmermann, C., Roseman, L., Erritzøe, D., Nutt, D., Stamatakis, E. A., Spreng, R. N., Xing, L., et al. (2023) · Brain · doi:10.1093/brain/awad311 · Cited by 31
Young, S. N. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120128 · Cited by 31
Schenberg, E. E., Tófoli, L. F., REZINOVSKY, D., & da Silveira, D. X. (2017) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000105 · Cited by 31
Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
Fox, K. C. R., Girn, M., Parro, C., & Kalina Christoff, A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316556238.007 · Cited by 30
Safety pharmacology of acute psilocybin administration in healthy participants
Straumann, I., Holze, F., Becker, A., Ley, L., Halter, N., & Liechti, M. E. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104060 · Cited by 30
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 30
Padawer-Curry, J. A., Krentzman, O. J., Kuo, C., Wang, X., Bice, A. R., Nicol, G. E., Snyder, A. Z., Siegel, J. S., McCall, J. G., & Bauer, A. Q. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02069-z · Cited by 30
Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
Messell, C., Summer, L., Bonde, L. O., Beck, B. D., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873455 · Cited by 30
Ko, K., Carter, B., Cleare, A. J., & Rucker, J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s426193 · Cited by 30
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 29
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials
Kishon, R., Modlin, N. L., Cycowicz, Y. M., Mourtada, H., Wilson, T., Williamson, V., Cleare, A. J., & Rucker, J. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00068-9 · Cited by 29
Yaden, D. B., & Anderson, D. E. (2021) · Philosophical Psychology · doi:10.1080/09515089.2021.1915972 · Cited by 29
Stocker, K., Hartmann, M., Ley, L., Becker, A., Holze, F., & Liechti, M. E. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231199112 · Cited by 29
Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy
McCulloch, D. E.-W., Olsen, A. S., Ozenne, B., Larsen, K. O., Stenbæk, D. S., Armand, S., Madsen, M. K., Knudsen, G. M., & Fisher, P. M. (2026) · Nature Communications · doi:10.1038/s41467-026-74215-5 · Cited by 29
Schwartzman, D. J., Schartner, M. M., Ador, B. B., Simonelli, F., Chang, A. Y.-C., & Seth, A. K. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/511766 · Cited by 29
Orsolini, L., St John-Smith, P., McQueen, D., Papanti, D., Corkery, J., & Schifano, F. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666161111114838 · Cited by 28
Psilocybin for major depressive disorder: a systematic review of randomized controlled studies
Li, L., Mo, Y., Shi, Z.-M., Huang, X., Ning, Y.-P., Wu, H., Yang, X.-H., & Zheng, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1416420 · Cited by 28
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports
Yildirim, B., Sahin, S. S., Gee, A., Jauhar, S., Rucker, J., Salgado‐Pineda, P., Pomarol‐Clotet, E., & McKenna, P. J. (2024) · Psychological Medicine · doi:10.1017/s0033291724002496 · Cited by 28
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
Collins, H. M. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae057 · Cited by 28
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
Rogers, S. A., Heller, E. A., & Corder, G. F. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01964-9 · Cited by 28
Hypnotic suggestion produces mystical-type experiences in the laboratory: A demonstration proof.
Lynn, S. J., & Evans, J. V. (2017) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000105 · Cited by 28
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
Kaminski, D., & Reinert, J. P. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231205645 · Cited by 27
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 27
Tagliazucchi, E., Zamberlán, F., Cavanna, F., de la Fuente, L., Romero, C., Perl, Y. S., & Pallavicini, C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.720066 · Cited by 27
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V., Ramaekers, J. G., & Mason, N. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.883869 · Cited by 26
Psychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 26
Narratives of the mystical among users of psychedelics
Pedersen, W., Copes, H., & Gashi, L. (2021) · Acta Sociologica · doi:10.1177/0001699320980050 · Cited by 26
Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 26
Self-citationThe psychedelic effects of cannabis: A review of the literature
Wolinsky, D., Barrett, F. S., & Vandrey, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231209194 · Cited by 26
Moral Enhancement Should Target Self-Interest and Cognitive Capacity
Ahlskog, R. (2017) · Neuroethics · doi:10.1007/s12152-017-9331-x · Cited by 26
Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.033 · Cited by 26
Self-citationSerotonin and Serotonin Receptors in Hallucinogen Action
Halberstadt, A. L., & Nichols, D. E. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70103-x · Cited by 26
Murphy, R. J., Sumner, R. L., Evans, W., Menkes, D. B., Lambrecht, I., Ponton, R., Sundram, F., Hoeh, N. R., Ram, S., Reynolds, L., et al. (2021) · Trials · doi:10.1186/s13063-021-05243-3 · Cited by 25
Foundations for Training Psychedelic Therapists
Phelps, J., & Henry, J. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_266 · Cited by 25
Psychedelic Mystical Experience: A New Agenda for Theology
Cole‐Turner, R. (2022) · Religions · doi:10.3390/rel13050385 · Cited by 25
Jensen, M. E., Stenbæk, D. S., Juul, T. S., Fisher, P. M., Ekstrøm, C. T., Knudsen, G. M., & Fink‐Jensen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066019 · Cited by 25
Isham, A., Elf, P., & Jackson, T. P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1051478 · Cited by 25
Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia
Irvine, A., Luke, D. P., Harrild, F., Gandy, S., & Watts, R. (2023) · Psychoactives · doi:10.3390/psychoactives2020012 · Cited by 25
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 25
Magic truffles or Philosopher's stones: a legal way to sell psilocybin?
Pellegrini, M., Rotolo, M. C., Marchei, E., Pacifici, R., Saggio, F., & Pichini, S. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1400 · Cited by 25
Philosophy and classic psychedelics: A review of some emerging themes
Letheby, C., & Mattu, J. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00191 · Cited by 24
Psychedelics and the ‘inner healer’: Myth or mechanism?
Peill, J. M., Marguilho, M., Erritzøe, D., Barba, T., Greenway, K. T., Rosas, F. E., Timmermann, C., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241239206 · Cited by 24
Leth‐Petersen, S., Bundgaard, C., Hansen, M. A., Carnerup, M. A., Kehler, J., & Kristensen, J. L. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1253-y · Cited by 24
O'Donnell, K. C., Mennenga, S. E., Owens, L. T., Podrebarac, S. K., Baron, T., Rotrosen, J., Ross, S., Forcehimes, A. A., & Bogenschutz, M. P. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106976 · Cited by 23
Zhou, K., de Wied, D., Carhart-Harris, R. L., & Kettner, H. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgae560 · Cited by 23
Šabanović, M., Lazari, A., Blanco-Pozo, M., Tisca, C., Tachrount, M., Martins-Bach, A. B., Lerch, J. P., Walton, M. E., & Bannerman, D. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02439-2 · Cited by 23
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- Psychopharmacology
- Published
- 2011-06-15
- Volume
- 218
- Issue
- 4
- Pages
- 649-665
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3308357
- OpenAlex
- W2001101493
- Semantic Scholar
- b6a466d47ff14211f273622e5d0b584d06253237
- Cited by
- 932
- References
- 38
- Citations by year
- 2026: 59 · 2025: 97 · 2024: 115 · 2023: 110 · 2022: 107 · 2021: 94 · 2020: 64 · 2019: 65 · 2018: 48 · 2017: 51 · 2016: 40 · 2015: 18 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dose-response relationship, fear and anxiety, long-term psychological effects, psychedelic therapy
- MeSH terms
- Adult, Affect, Attitude, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Time Factors, Cross-Over Studies, Spirituality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
